American Society of Hirudotherapy

Atopic Eczema (Localized Refractory)

Investigational use for localized refractory eczema; evidence is limited to a few small studies without placebo or standard-care controls.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for atopic eczema. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for atopic eczema is investigational.
What evidence exists?
Tier C (investigational). Three small studies in people with eczema have been published (open-label studies of 27 and 20 patients, and a 29-patient comparison with venesection); none compared leech therapy with placebo or standard care, and they enrolled people with eczema in general rather than atopic dermatitis specifically. Evidence-based first-line care includes emollients, topical corticosteroids, topical calcineurin inhibitors, and for moderate-to-severe disease dupilumab or upadacitinib (all supported by extensive RCT data).
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness around eczematous plaques for 5 to 10 days
  • Itching and irritation at bite sites for days to weeks (may be prolonged in atopic skin)
  • Local skin infection or, rarely, Aeromonas infection (heightened in patients with eczema due to skin barrier disruption and S. aureus colonization)
  • Post-inflammatory hyperpigmentation more common in atopic patients
  • Allergic reaction to leech saliva (uncommon, but atopic patients have higher background atopy)
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Potential to trigger an eczema flare at or near application sites
  • Eczema herpeticum or impetiginization if applied to broken or weeping skin
  • Delay of evidence-based dupilumab or JAK-inhibitor therapy
Who should not consider this
  • Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
  • Patients with hemophilia or other bleeding disorders
  • Patients with anemia
  • Patients with eczema herpeticum or active impetiginization (skin infection emergencies)
  • Patients on systemic immunomodulators (higher infection risk)
  • Patients with widespread severe atopic dermatitis where systemic therapy is clearly indicated
  • Children — evidence base does not support pediatric use
  • Patients with widespread excoriation or secondary bacterial infection
  • Pregnant or breastfeeding patients
What to ask your clinician
  • Have I been evaluated by a dermatologist?
  • Have I had adequate trials of emollients, topical steroids, topical calcineurin inhibitors, or dupilumab/upadacitinib?
  • What evidence supports leech therapy for atopic eczema specifically?
  • What is the risk of triggering a flare or infection in compromised skin?
  • What is the realistic chance of benefit, and for how long?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the cost?
  • Are leeches from an FDA-registered supplier and used only once?
  • How will we know if treatment is working — by EASI score, photographs, or symptoms?
When to seek urgent care
  • Rapidly worsening eczema with painful clustered blisters (possible eczema herpeticum — emergency)
  • Spreading redness, warmth, pus, weeping, or red streaks (impetiginization or cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty
  • Severe flare with extensive skin denudation or signs of systemic illness

What this does NOT mean

  • This is not FDA-cleared for atopic eczema.
  • Small open-label studies (27 and 20 patients) are not evidence of efficacy in the general population.
  • Mechanism rationale (local anti-inflammation) does NOT establish clinical efficacy.
  • Atopic skin has a disrupted barrier and is at high risk for infection — leech bites add risk.
  • Leech therapy is not a substitute for emollients, topical therapy, or dupilumab/upadacitinib.
  • It does NOT mean leech application is safe on actively weeping, excoriated, or herpetically-infected skin — those settings carry serious risk.

Clinical Profile

Category
Dermatological
ICD-10
L20.0, L20.81, L20.84, L20.89, L20.9
Safety tier
Medium

Evidence Summary

PubMed-indexed evidence is limited to a few small studies in patients diagnosed with eczema (Ayurvedic vicarcika or Unani Nar Farsi), not specifically atopic dermatitis. One is an open-label trial without a control group (Shankar et al. 2014, PMID 25593404, n=27) in which leech applications were associated with a 55% reduction in the SCORAD index, a 54.45% reduction in the Eczema Area and Severity Index (EASI), and a 62.36% improvement in Dermatology Life Quality Index (DLQI), all P<0.01, with no adverse reactions reported (according to PubMed; DOI: https://doi.org/10.4103/0257-7941.147432). A second open-label single-arm study of 20 patients (Ulla et al. 2025, PMID 40293844) found significant improvement in EASI redness, edema, excoriation and lichenification, but not in total area involved (P=.24). A randomized comparison of leech application with venesection in 29 patients (Raval & Thakar 2012, PMID 23049187) favoured leeches but had no placebo or standard-care control. The 2004 monograph by Baskova and Isakhanyan also retells Russian reports that include patients with eczema or neurodermatitis, without patient numbers or eczema-specific results (see “What the books describe” below). Because the journal studies were small and either uncontrolled or lacked a placebo or standard-care control, their results cannot establish efficacy. Generalized atopic dermatitis is not appropriate for leech therapy, and standard care (emollients, topical corticosteroids, topical calcineurin inhibitors, and dupilumab or upadacitinib for moderate-to-severe disease) remains the standard. Leech bite sites may show post-inflammatory hyperpigmentation. ASH position: investigational only.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not describe atopic eczema as a separate condition: they name the chronic form of eczema and varicose eczema among the skin diseases in which leech treatment is recommended (noting that there are few publications on hirudotherapy in such conditions), and they retell experience of treating children, among whose diseases neurodermatitis is named; the book does not call this skin disease atopic[B1].
  • Rybakova (1998), as retold by the authors, prescribed hirudotherapy, among others, to patients with varicose eczema (as it is called in the book); a marked favorable effect is stressed, and in the lesions, as described, redness, infiltration and itching decreased; the number of patients and the results specifically in eczema are not singled out[B1].
  • O. N. Yakovleva (1999), as retold, treated children with a number of diseases, including neurodermatitis, with leeches; the text says the method is effective in the named diseases and that it is advisable to introduce it into the practice of the pediatric neurologist; whose conclusion this is — Yakovleva's herself or the book authors' — is not clear from the text, and there are no data specifically on neurodermatitis (how many children, how the treatment ended)[B1].
  • Michalsen et al. do not write about eczema, neurodermatitis or atopic dermatitis[B3].
  • Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure and acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent use of anticoagulants (especially long-term and daily), concurrent use of alcohol, individual intolerance and an extremely negative attitude of the patient toward leeches, and at high body temperature they advise refraining from leeches[B1].
  • Flecken and Michalsen, in the chapter on contraindications, call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia and bone-marrow suppression, according to them, any treatment involving blood removal is generally contraindicated; aspirin and clopidogrel are not contraindications in themselves, but at the first session they advise reducing the number of leeches and asking the patient about a tendency to bleed; in known allergy to proteins, according to them, the possibility of a reaction to the foreign proteins in leech saliva must be taken into account, in severe allergic predisposition with severe general reactions hirudotherapy is not performed, and in mild or uncertain intolerance it is possible together with antihistamines[B3].
  • In the appendix of Michalsen et al. (patient information and consent form), hirudotherapy is not performed, among other conditions, in blood diseases, acute gastric ulcer or erosive gastritis, immune deficiency (AIDS, chemotherapy), severe chronic diseases (advanced cancer, dialysis), a history of poor wound healing (for example, with poorly controlled diabetes, obesity and long-term cortisone treatment), known allergy to the active substances in leech saliva, and a tendency to keloids or scarring; the same document asks the patient not to use perfumed lotions, shower gels, medicinal ointments and oils on the day before and on the day of the procedure[B3].
  • For adults with atopic dermatitis that does not respond to other treatment, Flecken and Michalsen write nothing separately and note only the general point: in marked immunosuppression (they name chemotherapy) hirudotherapy is never performed, and they classify immune diseases as relative contraindications; they do not name drugs in atopic dermatitis, so whether this applies to such patients is not clear from the text[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Eczema herpeticum or active impetiginization
  • Severe ongoing immunomodulator therapy
  • Widespread excoriation with secondary infection

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.